Back

Antibody Responses to SARS-CoV-2 Vaccine in Nursing Home Residents Support a Bi-Annual Update Schedule

Paxitzis, A. N.; Oyebanji, O. A.; Olagunju, O. J.; Keresztesy, D.; Payne, M.; Ragavapuram, V.; Sundheimer, N.; See, E.; Wilk, D.; Cao, Y.; Abul, Y.; Nugent, C.; Dickerson, E.; Wallace, T.; Holland, L.; Nanda, A.; Pfeifer, W. M.; Balazs, A. B.; King, C. L.; Gravenstein, S.; Canaday, D. H.; Wilson, B. M.; Bosch, J.

2025-01-16 geriatric medicine
10.1101/2025.01.09.25320262
Show abstract

BackgroundThe COVID-19 pandemic has greatly affected nursing home residents (NHRs), a vulnerable group with high rates of illness and death. While vaccination is essential for reducing infections and severe outcomes in the short term, it is important to understand how long antibody levels and neutralizing activity last. This understanding will help us create effective public health strategies for the long term. According to current CDC guidelines, individuals over the age of 65 should receive a booster dose six months after their previous vaccination. MethodsThis observational retrospective cohort study analyzed post-vaccination serum from samples with up to 400 days of follow-up from 697 NHRs and 127 healthcare workers (HCWs) across Northeast Ohio and Rhode Island. Analyses were conducted to model decay rates of both neutralizing and binding antibody titers and the impact of previous exposures to SARS-CoV-2 on these decay rates. ResultsResults indicate that NHRs show Wuhan and Omicron BA.4/5 neutralizing and binding antibody titers diminish significantly from 2 weeks to 12 months post-vaccination. NHRs with prior infection show higher peak antibody titers and slower decay than those naive to infection. Antibody levels after vaccination for infection-naive NHR residents lagged HCW and NHR with prior infection, but then decayed at a similar rate. ConclusionThe immunologic findings in this cohort of NHR are in line with the existing real-world clinical effectiveness data in older individuals and support the CDC recommendation of a bi-annual vaccination to reduce severe COVID-19 outcomes in persons age 65 and older.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
PLOS ONE
based on 1737 papers
Top 21%
18.4%
2
Journal of the American Geriatrics Society
based on 12 papers
Top 0.1%
14.1%
3
Journal of the American Medical Directors Association
based on 12 papers
Top 0.1%
11.0%
4
Age and Ageing
based on 27 papers
Top 0.3%
8.2%
50% of probability mass above
5
Clinical Infectious Diseases
based on 219 papers
Top 5%
5.1%
6
BMJ Open
based on 553 papers
Top 27%
3.2%
7
Vaccine
based on 140 papers
Top 2%
3.2%
8
BMC Geriatrics
based on 15 papers
Top 0.5%
3.0%
9
Scientific Reports
based on 701 papers
Top 49%
3.0%
10
The Lancet Healthy Longevity
based on 11 papers
Top 0.1%
2.6%
11
The Journals of Gerontology: Series A
based on 19 papers
Top 1%
2.6%
12
eClinicalMedicine
based on 55 papers
Top 1%
1.9%
13
eBioMedicine
based on 82 papers
Top 2%
1.7%
14
Canadian Medical Association Journal
based on 15 papers
Top 0.3%
1.7%
15
International Journal of Epidemiology
based on 65 papers
Top 5%
1.4%
16
JAMA Network Open
based on 125 papers
Top 12%
1.4%
17
Aging
based on 18 papers
Top 3%
1.3%
18
Frontiers in Public Health
based on 135 papers
Top 21%
1.3%
19
BMC Medicine
based on 155 papers
Top 19%
0.9%
20
The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
based on 15 papers
Top 1%
0.9%
21
Cureus
based on 64 papers
Top 15%
0.9%
22
Open Forum Infectious Diseases
based on 124 papers
Top 11%
0.7%
23
International Journal of Environmental Research and Public Health
based on 116 papers
Top 23%
0.7%